[go: up one dir, main page]

DK3166595T3 - Mikroniseret insulin, mikroniserede insulinanaloger, og fremgangsmåder til fremstilling deraf - Google Patents

Mikroniseret insulin, mikroniserede insulinanaloger, og fremgangsmåder til fremstilling deraf Download PDF

Info

Publication number
DK3166595T3
DK3166595T3 DK15747618.5T DK15747618T DK3166595T3 DK 3166595 T3 DK3166595 T3 DK 3166595T3 DK 15747618 T DK15747618 T DK 15747618T DK 3166595 T3 DK3166595 T3 DK 3166595T3
Authority
DK
Denmark
Prior art keywords
micronized insulin
producing
methods
micronized
analogs
Prior art date
Application number
DK15747618.5T
Other languages
English (en)
Inventor
Jeffrey Ding
Aili Bo
Mary Ziping Luo
Jack Yongfeng Zhang
Original Assignee
Amphastar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amphastar Pharmaceuticals Inc filed Critical Amphastar Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3166595T3 publication Critical patent/DK3166595T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK15747618.5T 2014-07-08 2015-07-08 Mikroniseret insulin, mikroniserede insulinanaloger, og fremgangsmåder til fremstilling deraf DK3166595T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462022026P 2014-07-08 2014-07-08
PCT/US2015/039625 WO2016007682A1 (en) 2014-07-08 2015-07-08 Micronized insulin, micronized insulin analogues, and methods of manufacturing the same

Publications (1)

Publication Number Publication Date
DK3166595T3 true DK3166595T3 (da) 2019-08-05

Family

ID=53783921

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15747618.5T DK3166595T3 (da) 2014-07-08 2015-07-08 Mikroniseret insulin, mikroniserede insulinanaloger, og fremgangsmåder til fremstilling deraf

Country Status (10)

Country Link
US (1) US10258573B2 (da)
EP (1) EP3166595B1 (da)
JP (1) JP6530480B2 (da)
CN (1) CN106794156B (da)
BR (1) BR112017000175B1 (da)
CA (1) CA2954287C (da)
DK (1) DK3166595T3 (da)
MX (1) MX375021B (da)
RU (1) RU2694063C2 (da)
WO (1) WO2016007682A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3166595T3 (da) 2014-07-08 2019-08-05 Amphastar Pharmaceuticals Inc Mikroniseret insulin, mikroniserede insulinanaloger, og fremgangsmåder til fremstilling deraf
US10322168B2 (en) 2016-01-07 2019-06-18 Amphastar Pharmaceuticals, Inc. High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
US20210290733A1 (en) * 2018-07-16 2021-09-23 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Injectable micronized human insulin

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
CA2183577C (en) 1994-03-07 2007-10-30 John S. Patton Methods and compositions for pulmonary delivery of insulin
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
EP1005490B1 (en) * 1997-03-20 2006-03-29 Novo Nordisk A/S Zinc free insulin crystals for use in pulmonary compositions
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
DK2280020T3 (da) 1999-06-29 2016-05-02 Mannkind Corp Farmaceutiske formuleringer omfattende et peptid kompleksbundet til et diketopiperazin
WO2001000674A1 (en) 1999-06-29 2001-01-04 Eli Lilly And Company Insulin crystals for pulmonary administration
US7087246B2 (en) 2000-06-27 2006-08-08 Mi Tech Company Limited Controlled release preparation of insulin and its method
DE60138641D1 (de) 2000-10-27 2009-06-18 Baxter Healthcare Sa Herstellung von mikrokügelchen
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
DE10235168A1 (de) * 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
GB0300427D0 (en) * 2003-01-09 2003-02-05 Univ Strathclyde Pharmaceutical composition
JP2007531701A (ja) 2003-07-18 2007-11-08 バクスター・インターナショナル・インコーポレイテッド 制御された相分離により調製される小球状粒子の作製方法、使用および組成物
EP1675571A2 (en) * 2003-09-30 2006-07-05 Spherics, Inc. Nanoparticulate therapeutic biologically active agents
EP1734938B1 (en) 2004-03-26 2012-06-20 Universita' Degli Studi Di Parma Insulin highly respirable microparticles
EP2036572A1 (en) * 2007-09-04 2009-03-18 Novo Nordisk A/S Process for drying a protein, a protein particle and a pharmaceutical composition comprising the protein particle
EP2811980A4 (en) 2012-01-31 2015-12-23 Cerulean Pharma Inc POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS AND METHODS OF USE THEREOF
DK3166595T3 (da) 2014-07-08 2019-08-05 Amphastar Pharmaceuticals Inc Mikroniseret insulin, mikroniserede insulinanaloger, og fremgangsmåder til fremstilling deraf

Also Published As

Publication number Publication date
CN106794156A (zh) 2017-05-31
US10258573B2 (en) 2019-04-16
EP3166595B1 (en) 2019-05-15
CA2954287C (en) 2020-12-22
MX2017000027A (es) 2017-05-01
RU2017103751A (ru) 2018-08-08
EP3166595A1 (en) 2017-05-17
BR112017000175B1 (pt) 2023-11-21
WO2016007682A1 (en) 2016-01-14
RU2017103751A3 (da) 2018-08-08
US20160008287A1 (en) 2016-01-14
JP2017520593A (ja) 2017-07-27
CN106794156B (zh) 2021-03-09
RU2694063C2 (ru) 2019-07-09
BR112017000175A2 (pt) 2017-10-31
JP6530480B2 (ja) 2019-06-12
MX375021B (es) 2025-03-06
CA2954287A1 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
DK3204413T3 (da) Bærerantistofsammensætninger og fremgangsmåder til fremstilling og anvendelse heraf
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
HUE047784T2 (hu) Anti-TIM3 antitestek és alkalmazási eljárások
DK3125836T3 (da) Vejrtrækningshjæpeapparat
PL3167096T3 (pl) Dwuetapowy sposób nanoszenia
DK3160470T3 (da) Analoger af pridopidin, fremstilling og anvendelse heraf
IL251988A0 (en) Glycan-interacting compounds and methods of use
IL251505A0 (en) Neuroactive compounds and methods of use thereof
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
DK3153169T3 (da) Fremgangsmåde til behandling af tumor, farmaceutisk sammensætning og medicinæskesæt
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3228731T3 (da) Oxygen-genererende anode
DK3171700T3 (da) Infusionsanlæg
DK3155017T3 (da) Forbedrede lægemidler til insulinresistens
DK3204150T3 (da) Fremgangsmåde til at producere nanopartikler
DK3159296T3 (da) Reb til elevator og fremstillingsfremgangsmåde dertil
DK3389669T3 (da) Triterpensaponinvarianter, syntesefremgangsmåder og anvendelse deraf
DK3374495T3 (da) Forbedrede fremgangsmåder til vævsfremstilling
DK3431460T3 (da) Ny formulering og fremgangsmåde til syntese
DK3154677T3 (da) Amorft mesoporøst alumina med høj konnektivitet og fremgangsmåde til fremstilling deraf
DK3225627T5 (da) Tripeptidforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK3166595T3 (da) Mikroniseret insulin, mikroniserede insulinanaloger, og fremgangsmåder til fremstilling deraf
DK3181556T3 (da) Mikromolekyleforbindelse, fremgangsmåde til syntese og anvendelse deraf